Shelter Pharma Ltd — Important, 27-06-2026: Company Update

Shelter Pharma reported audited financial results for H2 and the full financial year 2026, with revenue up 44% to 73.13 Cr and PAT up 25% to 9.03 Cr. The company aims for 200 Cr in annual revenues by FY2030, driven by capacity expansion, including a new 12-15 Cr manufacturing facility, and launching high-margin nutraceutical products. Strategic expansion into new domestic states and international markets, particularly Africa and the Middle East, fuels growth. A 42.44 Cr preference share issue for working capital and a 2.5 Cr land acquisition, largely funded by internal accruals, support these initiatives.